Egyptian trial tests tapered versus abrupt semaglutide stop after bariatric surgery
The phase 4 randomized, double-blind study targets patients who regained weight or responded poorly after metabolic surgery and cannot afford indefinite therapy.
PR
By Priya Raman · Science Reporter
Oct 5 08:00 ETSource: ClinicalTrials.gov
The wire
- 01NCT07859176, sponsored by Egypt's General Committee of Teaching Hospitals and Institutes, is a phase 4 randomized double-blind trial comparing gradual semaglutide dose reduction with abrupt cessation after metabolic and bariatric surgery, starting October 2026.
- 02Investigators note STEP 1 extension participants regained two thirds of lost weight a year after stopping, and that clinicians already taper over 8 to 12 weeks on anecdotal evidence alone.
- 03The trial is not yet recruiting and no enrollment figure is given; the comparable REST trial covers non-surgical patients, leaving post-surgical discontinuation untested.
From the source
Read at clinicaltrials.govTapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery
NCT07859176 · PHASE4 · NOT YET RECRUITING · Sponsor: General Committee of Teaching Hospitals and Institutes, Egypt · Conditions: Morbid Obesity.
Source URL https://clinicaltrials.gov/study/NCT07859176
